Skip to main content
. 2019 Dec 5;8(12):1577. doi: 10.3390/cells8121577

Figure 5.

Figure 5

Survival of patients treated with MSC-FFM. (A) Six-month overall survival estimates for the entire cohort (solid black line), for children (solid ochre line) and for adults (solid maroon line) were 64% (95% CI 54–74%), 69% (95% CI 58–82) and 54% (95% CI 39–76), respectively. OS was higher than recently published results from comparable cohort that received the best available therapy (Garcia-Cadenas et al. (2017) BMT 52:107–113, Ref. [2]). (B) Six-months cumulative incidence of death from underlying disease (solid black line) and from other causes (dashed black line) were 3% (95% CI 0–7) and 33% (95% CI 23–43), respectively.